Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
229 hedge funds and large institutions have $3.51B invested in Global Blood Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 52 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
10% less call options, than puts
Call options by funds: $27.6M | Put options by funds: $30.6M
9% less funds holding
Funds holding: 253 → 229 (-24)
14% less capital invested
Capital invested by funds: $4.09B → $3.51B (-$590M)
42% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$56.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$55.5M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$45.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$43M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$38.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$158M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$79.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22.3M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$18.6M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$18.2M |
GBT Hedge Fund Activity: Q3 2020 in Review
229 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2020, worth a combined $3.51B — down 14% from $4.09B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of GBT and 30 opened new positions — a net loss of 22 holders — while 76 trimmed existing stakes and 91 added.
The largest buyer was Janus Henderson Group, adding an estimated $56.6M. The largest seller was Fidelity Investments, cutting an estimated $158M.
- 229 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2020, down from 253 in Q2 2020.
- Funds reported $3.51B of Global Blood Therapeutics, Inc. stock for Q3 2020, down 14% quarter-over-quarter.
- 30 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2020 and 52 closed out, a net change of -22 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2020 was Janus Henderson Group, an estimated $56.6M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2020 was Fidelity Investments, an estimated $158M sold.
Based on aggregated 13F filings for Q3 2020.